StockData

Precigen vs UroGen Pharma

PGEN and URGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PGEN and URGN compare

Precigen and UroGen Pharma are about the same size, with market caps of $1.5B and $1.5B.

UroGen Pharma scores higher on the StockData Score (6 against 2 for Precigen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPGENURGN
Size and price
Market cap$1.5B$1.5B
Share price$4.29$29.87
Change, 1 year−11.5%25.7%
Change, 5 years11.1%146%
Beta (5Y)1.202.73
Employees20291
StockData Score
Total score26 (better)
Valuation score00
Growth score03 (better)
Performance score02 (better)
Health score2 (better)1
Dividend score00
Valuation
P/S–7.7×
P/B35.2×–
FCF yield−7.5% (better)−10.9%
Growth
Revenue growth (TTM)–100%
Revenue growth, 5Y average−21.3%56.2% (better)
Profitability
Gross margin–90.8%
Operating margin–−35.3%
Net margin–−51.7%
FCF margin–−84.3%
Return on equity−4640%–
Financial health
Debt / equity2.15–
Current ratio4.58 (better)3.80
Altman Z-score−11.14−2.55 (better)
Piotroski F-score2 (better)0
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions39.2%86.8%
Held by insiders44.9%5.6%
Insider net buying, 12 months−$32.5M−$4.5M (better)
Superinvestors holding1–
Short interest, % of float22.8%11.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.